- Home
- / RAPT Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
RAPT Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2
2024-10-29
Market Capitalization
$69.8 M
2024-10-29
Revenue
$1.5 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 03, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.0M | 3.8M | 1.5M | |||||
| General and administrative expense | 3.7M | 5.2M | 8.7M | 12.8M | 16.0M | 20.2M | 26.1M | 28.9M |
| Operating expense total | 29.3M | 36.9M | 43.6M | 58.3M | 87.3M | 136.1M | ||
| EBIT | (29.3M) | (36.9M) | (53.2M) | (69.2M) | (85.8M) | (127.1M) | (136.1M) | |
| EBIT margin, % | -1055.4% | -5618.5% | ||||||
| Pre tax profit | (42.3M) | (51.9M) | (69.2M) | (83.8M) | (116.8M) | (129.9M) | ||
| Income tax expense | 660.0K | 990.0K | ||||||
| Net Income | (29.1M) | (36.1M) | (52.9M) | (69.2M) | (83.8M) | (116.8M) | (129.9M) | |
| EPS | (2.6) | (3.0) | (3.2) |